Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer
NCT04049331Phase 2Recruiting
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
- Start
- Mar 2021
- Primary completion
- Jan 2027
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of testosterone undecanoate in Hypogonadism, myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS), sponsored by Seattle Institute for Biomedical and Clinical Research. Started Mar 2021; status: recruiting.
02
Drugs
testosterone undecanoate
03
Conditions
Hypogonadismmyalgic encephalomyelitis chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT04049331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049331.